ISM1745 / Insilico Medicine - LARVOL DELTA

ISM1745, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer (AACR 2026) - "Moreover, when combined with ISM3412, an inhibitor of MAT2A, which catalyzes formation of SAM, ISM1745 exhibits significant synergistic anti-tumor activity, highlighting its promise as part of a combinatorial strategy for targeting MTAP-deficient cancers.In addition to its robust biological potency and high selectivity, ISM1745 exhibits favorable drug-like properties, including optimal in vitro ADMET profiles, excellent in vivo exposure, low clearance (CL<30% Qh in non-rodent species), and moderate to high oral bioavailability across multiple preclinical species. Taken together, these findings support ISM1745 as a potent and selective MTA-cooperative PRMT5 inhibitor with robust anti-tumor efficacy, providing potential therapy for treatment of MTAP-deleted cancers."

Oncology • ANXA5 • MAT2A • MTAP